Benzoic Acid

Benzoic Acid

SCHEMBL1879517

O=C(O)c1ccccc1.O=C1N=Nc2cccnc21

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D

The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 3/20 0.45
TSHR P16473 2/20 0.45
DAO P14920 1/20 0.45
KDM4E B2RXH2 5/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
KDM6B O15054 1/20 0.41
KDM4A O75164 1/20 0.41
KDM5C P41229 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
KDM2A Q9Y2K7 1/20 0.41
KDM3A Q9Y4C1 1/20 0.41
ALDH1A1 P00352 3/20 0.41
APP P05067 1/20 0.41
GAA P10253 1/20 0.41
HCAR3 P49019 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
CA12 O43570 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL300666 0.84 TDP2 (0.46) KDM4ETDP1KMT2AMEN1ALDH1A1
Acetic Acid SCHEMBL9604110 0.75 TDP1 (0.42) TSHRKDM4ETDP1KMT2AMEN1
SCHEMBL388585 0.73 TDP2 (0.48) KDM4ETDP1KMT2AMEN1ALDH1A1
Benzoic Acid SCHEMBL28624673 0.71 NAPRT (0.61) NAPRTTSHRDAOKDM4ETDP1
Benzoic Acid SCHEMBL27993061 0.69 NAPRT (0.64) NAPRTTSHRDAOKDM4EKMT2A
Dipyridyl SCHEMBL28117961 0.69 KDM4E (0.75) NAPRTTSHRDAOKDM4ESMN1; SMN2
Benzoic Acid SCHEMBL11599602 0.67 TSHR (0.88) NAPRTTSHRDAOTDP1ALDH1A1
Benzoic Acid SCHEMBL177939 0.67 TSHR (0.88) NAPRTTSHRDAOTDP1ALDH1A1
Benzoic Acid SCHEMBL3966600 0.67 TSHR (1.00) NAPRTTSHRDAOTDP1ALDH1A1
Benzoic Acid SCHEMBL7719037 0.67 TSHR (1.00) NAPRTTSHRDAOTDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367671-B2 Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents AMGEN INC. (US) 2013-02-05 US disclosed
US-8314131-B2 Triazole fused heteroaryl compounds and methods of use thereof AMGEN INC. (US) 2012-11-20 US disclosed
US-8080546-B2 Pyrazolo-pyridinone derivatives and methods of use AMGEN INC. (US) 2011-12-20 US disclosed
US-20110105499-A1 Pyrazolo-Pyrazinone Compounds and Methods of Use Thereof AMGEN INC. (US) 2011-05-05 US disclosed
US-7846944-B2 Pyrazolo-pyridinone compounds and methods of use thereof AMGEN INC. (US) 2010-12-07 US disclosed
US-20100292234-A1 TRIAZOLE FUSED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF AMGEN INC. (US) 2010-11-18 US disclosed
EP-2152704-A1 PYRAZOLO-PYRIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE Amgen, Inc (US) 2010-02-17 EP disclosed
WO-2009117156-A1 PYRAZOLO-PYRAZINONE COMPOUNDS AND METHODS OF USE THEREOF AMGEN INC. (US) 2009-09-24 WO disclosed
US-20090137582-A1 Pyrazolo-pyridinone derivatives and methods of use AMGEN INC. (US) 2009-05-28 US disclosed
WO-2009055033-A1 PYRAZOLO-PYRIDINONE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2009-04-30 WO disclosed
WO-2009038784-A1 TRIAZOLE FUSED HETEROARYL COMPOUNDS AS P38 KINASE INHIBITORS AMGEN INC. (US) 2009-03-26 WO disclosed
US-20090012299-A1 Pyrazolo-pyridinone compounds and methods of use thereof AMGEN INC. (US) 2009-01-08 US disclosed
WO-2008137176-A1 PYRAZOLO-PYRIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE AMGEN INC. (US) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292234-A1 TRIAZOLE FUSED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF MAPK1, MAPK3, CNKSR1 NAPRT 2099/4885TSHR 1364/4885DAO 3174/4885
US-20110105499-A1 Pyrazolo-Pyrazinone Compounds and Methods of Use Thereof MAPK1, MAP3K1, MAP4K2 NAPRT 2091/4885TSHR 2083/4885DAO 2444/4885
US-20090012299-A1 Pyrazolo-pyridinone compounds and methods of use thereof MAPK1, MAP3K1, MAP4K2 NAPRT 1417/4885TSHR 2220/4885DAO 2163/4885
US-20090137582-A1 Pyrazolo-pyridinone derivatives and methods of use IL1B, IL1R1, IL1A NAPRT 1156/4885TSHR 1732/4885DAO 1548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.